文献速递冠心病血脂与心血管预防

药物洗脱支架PCI术后双联抗血小板治疗时长的网络荟萃分析

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
PubMed 文献 · Circulation · 2020-08-03

中位随访18个月,延长DAPT较12个月DAPT降低心肌梗死风险但增加大出血;短期DAPT后P2Y12抑制剂单药较12个月DAPT减少大出血。

要点

  • 延长DAPT(>12个月)较12个月DAPT降低心肌梗死风险,但大出血风险升高。
  • 短期DAPT后P2Y12抑制剂单药较12个月DAPT减少大出血,缺血终点无显著差异。
  • 急性冠脉综合征中延长DAPT较12个月DAPT降低心梗且未显著增加大出血。

核心结论

  • 与12个月DAPT相比,短期DAPT后P2Y12抑制剂单药可减少药物洗脱支架PCI术后大出血,而延长DAPT降低心肌梗死但以更多出血事件为代价。

主要发现

  • 中位随访18个月,延长DAPT较12个月DAPT降低心肌梗死风险(绝对风险差-3.8例/1000人年;相对风险0.68[95%CI 0.54-0.87])。
  • 延长DAPT较6个月DAPT降低心肌梗死风险(绝对风险差-4.6例/1000人年;相对风险0.61[0.45-0.83])。
  • 延长DAPT较短期DAPT后阿司匹林单药降低心肌梗死风险(绝对风险差-6.1例/1000人年;相对风险0.55[0.37-0.83])。
  • 延长DAPT较短期DAPT后P2Y12抑制剂单药降低心肌梗死风险(绝对风险差-3.7例/1000人年;相对风险0.69[0.51-0.95])。
  • 延长DAPT较其他所有DAPT组大出血风险更高;短期DAPT后P2Y12抑制剂单药较12个月DAPT减少大出血;不同DAPT策略间死亡率无显著差异。

关键数值与推荐

  • 短期DAPT后P2Y12抑制剂单药较12个月DAPT减少大出血,缺血终点无显著差异。
  • 急性冠脉综合征中延长DAPT较12个月DAPT降低心肌梗死且未显著增加大出血。
  • 6个月DAPT或短期DAPT后阿司匹林单药较12个月DAPT在缺血终点或大出血方面无显著差异。

临床怎么用

  • 高出血风险患者可考虑短期DAPT后P2Y12抑制剂单药以降低大出血。
  • 缺血高风险患者可考虑延长DAPT(>12个月)以降低心肌梗死,但需权衡出血风险。
  • 急性冠脉综合征患者延长DAPT较12个月DAPT降低心肌梗死且未显著增加大出血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting stents remains uncertain. We compared short-term (<6-month) DAPT followed by aspirin or P2Y12 inhibitor monotherapy; midterm (6-month) DAPT; 12-month DAPT; and extended-term (>12-month) DAPT after percutaneous coronary intervention with drug-eluting stents. METHODS: Twenty-four randomized, controlled trials were selected using Medline, Embase, Cochrane library, and online databases through September 2019. The coprimary end points were myocardial infarction and major bleeding, which constituted the net clinical benefit. A frequentist network meta-analysis was conducted with a random-effects model. RESULTS: In 79 073 patients, at a median follow-up of 18 months, extended-term DAPT was associated with a reduced risk of myocardial infarction in comparison with 12-month DAPT (absolute risk difference, -3.8 incident cases per 1000 person-years; relative risk, 0.68 [95% CI, 0.54-0.87]), midterm DAPT (absolute risk difference, -4.6 incident cases per 1000 person-years; relative risk, 0.61 [0.45-0.83]), and short-term DAPT followed by aspirin monotherapy (absolute risk difference, -6.1 incident cases per 1000 person-years; relative risk, 0.55 [0.37-0.83]), or P2Y12 inhibitor monotherapy (absolute risk difference, -3.7 incident cases per 1000 person-years; relative risk, 0.69 [0.51-0.95]). Conversely, extended-term DAPT was associated with a higher risk of major bleeding than all other DAPT groups. In comparison with 12-month DAPT, no significant differences in the risks of ischemic end points or major bleeding were observed with midterm or short-term DAPT followed by aspirin monotherapy, with the exception that short-term DAPT followed by P2Y12 inhibitor monotherapy was associated with a reduced risk of major bleeding. There were no significant differences with respect to mortality between the different DAPT strategies. In acute coronary syndrome, extended-term in comparison with 12-month DAPT was associated with a reduced risk of myocardial infarction without a significant increase in the risk of major bleeding. CONCLUSIONS: The present network meta-analysis suggests that, in comparison with 12-month DAPT, short-term DAPT followed by P2Y12 inhibitor monotherapy reduces major bleeding after percutaneous coronary intervention with drug-eluting stents, whereas extended-term DAPT reduces myocardial infarction at the expense of more bleeding events.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Khan SU, Singh M, Valavoor S, et al. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation. 2020. PMID: 32795096. doi:10.1161/CIRCULATIONAHA.120.046308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。